Rockefeller Capital Management’s INmune Bio INMB Stock Holding History

Rockefeller Capital Management’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.08K	Hold	2,500	–	–	﹤0.01%	4289
2026 Q1	$2.83K	Hold	2,500	–	–	﹤0.01%	4354
2025 Q4	$3.9K	Hold	2,500	–	–	﹤0.01%	4144
2025 Q3	$5.17K	Buy	+2,500	New	+$5.72K	﹤0.01%	3860
2024 Q1	–	Sell	-18,220	Closed	-$205K	–	1699
2023 Q4	$205K	Buy	+18,220	New	+$153K	﹤0.01%	1530
2020 Q3	–	Sell	-50	Closed	–	–	2680
2020 Q2	$0	Buy	+50	New	+$252	﹤0.01%	2626

Other funds holding INMB

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rockefeller Capital Management's INMB Position: Q2 2026 in Review

Rockefeller Capital Management held its INmune Bio (INMB) position steady in Q2 2026 at 2,500 shares worth $4.08K. The position accounts for ﹤0.01% of the portfolio, ranked #4289.

Rockefeller Capital Management first reported a position in INMB in Q2 2020 and has held it in 6 quarters since. The position peaked at $205K in Q4 2023. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

Rockefeller Capital Management held 2,500 shares of INmune Bio worth $4.08K as of Q2 2026.
Rockefeller Capital Management left its INmune Bio share count unchanged in Q2 2026.
INmune Bio made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4289 holding.
Rockefeller Capital Management first reported a position in INmune Bio in Q2 2020 and has held it in 6 quarters since.
Rockefeller Capital Management's INmune Bio position peaked at $205K in Q4 2023.
82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.